ReviewClinical Medicine Insights. Oncology2019
The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer.
Review in Clinical Medicine Insights. Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review.Frontiers in endocrinology · 2022Pooled it
- Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data.PloS one · 2025Article
- Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review.Current oncology reports · 2024Review
- Cancer research in Lebanon: Scope of the most recent publications of an academic institution (Review).Oncology letters · 2024Review
- Low-Dose Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Case Report.Cureus · 2024Article
- Longitudinal change in castration-resistant prostate cancer biomarker AST/ALT ratio reflects tumor progression.Scientific reports · 2023Article
- Crafting a Personalized Prognostic Model for Malignant Prostate Cancer Patients Using Risk Gene Signatures Discovered through TCGA-PRAD Mining, Machine Learning, and Single-Cell RNA-Sequencing.Diagnostics (Basel, Switzerland) · 2023Article
- Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice.Frontiers in oncology · 2023Article
- Antiandrogenic Effects of a Polyphenol inInternational journal of molecular sciences · 2022Article
- Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study.BJUI compass · 2022Article
- Article
- Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer.Scientific reports · 2021Article
- Treatment and trials in non-metastatic castration-resistant prostate cancer.Nature reviews. Urology · 2021Review
- Article
- 2020 Korean guidelines for the management of metastatic prostate cancer.The Korean journal of internal medicine · 2021Review
- Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agents.Heliyon · 2021Article
- Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPactCancer management and research · 2021Article
- Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer.Cancer management and research · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-metastatic castration-resistant prostate cancer (nmCRPC) is a heterogeneous disease with variable potential in developing into overt metastases. It is an area of increased unmet need in advanced prostate cancer and for which there had been no great treatments until recent US Food and Drug Administration (FDA) approval of 2 novel anti-androgens apalutamide and enzalutamide, which were both approved given benefit in metastasis-free survival. Early data on the use of darolutamide, another novel anti-androgen, are also explored. This review discusses the pivotal trials that led to the approval of apalutamide and enzalutamide in the nmCRPC setting and discusses the key promises and challenges with the use of these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.